AcelRx Pharmaceuticals Q3 2023 Gaap EPS $(0.08) Beats $(0.28) Estimate, Sales $117.00K Miss $130.00K Estimate

11/8/23 5:16:46 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ACRX alert in real time by email

AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.28) by 71.43 percent. This is a 91.49 percent increase over losses of $(0.94) per share from the same period last year. The company reported quarterly sales of $117.00 thousand which missed the analyst consensus estimate of $130.00 thousand by 10.00 percent. This is a 76.92 percent decrease over sales of $507.00 thousand the same period last year.

Get the next $ACRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ACRX

Date	Price Target	Rating	Analyst
8/17/2021	$7.00 → $5.00	Buy	HC Wainwright & Co.

More analyst ratings

$ACRX
Financials

Live finance-specific insights

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authorization (EUA) of Niyad™ submitted to the FDA in April; registrational study set to initiate in Q4 2023 Proforma $17.4 million in cash as of June 30, 2023, including gross proceeds from financing closed in July 2023 Senior debt with Oxford fully repaid in Q2 2023 Webcast and conference call to be held today at 4:30 p.m. EDT SAN MATEO, Calif., Aug. 10, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commer
8/10/23 4:05:00 PM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
HAYWARD, Calif., July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2023 financial results after market close on Thursday, August 10, 2023, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.acelrx.com and cl
7/27/23 4:05:00 PM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webcast and conference call to be held today at 4:30 p.m. EDT HAYWARD, Calif., May 10, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2023 financial results and provided a corporate update. "We have embarked on a new AcelRx chapter by closing the DSUVIA transaction and submitting the request for a
5/10/23 4:05:00 PM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care

$ACRX
Market Insights

Live Market Insights

AcelRx Pharmaceuticals Announces Rebranding With Name Change to Talphera; To Trade On Nasdaq Under Ticker Symbol "TLPH" Effective Jan. 10, 2024
Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settingsTalphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10
1/9/24 9:11:10 AM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care
AcelRx Pharmaceuticals Announces Publication Of Study Evaluating Anticoagulation Practices For Continuous Renal Replacement Therapy In The U.S.
Use of CRRT increased during COVID and remained at these higher utilization levelsStudy results demonstrate challenges physicians have with heparin and citrate, the two currently available CRRT anticoagulants SAN MATEO, Calif., Dec. 12, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a quantitative market research study evaluating current U.S. physician anticoagulation use during continuous renal replacement therapy (CRRT) in patients with acute kidney injury in the intensive care unit. The o
12/12/23 8:37:16 AM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Shares of Green Giant Inc. (NASDAQ:GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers NextPlay Technologies, Inc. (NASDAQ:NXTP) shares rose 62.8% to $0.6841 in pre-market trading. NextPlay Technologies recently received notice from Nasdaq stating that it did not comply with listing rule. Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares gained 29.3% to $0.83 in pre-market trading. Onconova Therapeutics' preclinical narazaciclib data at SABCS highlighted differentiated anti-tumor activity v. other CDK4/6i's. Macy's, Inc.
12/11/23 7:59:28 AM ET
$ACRX
$BMEA
$CI
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
EDP Services

$ACRX
Leadership Updates

Live Leadership Updates

AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors
HAYWARD, Calif., Nov. 23, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Jill Broadfoot to the company's Board of Directors. Ms. Broadfoot currently serves as the Chief Financial Officer (CFO) of aTyr Pharma, Inc., a position she has held since July 2018. Prior to joining aTyr, Ms. Broadfoot served as CFO of Emerald Health Pharmaceuticals and Emerald Health Bioceuticals, where she was responsible for establishing operations for the U.S.-based pharmaceutical and bioceutical entities as well as
11/23/21 5:09:00 PM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company's board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Dr. Desai to the Board and look forward to working with her to pursue long-term value creation. Her substantial expertise in international pharmaceutical licensing, combined with her background in drug development and commercialization will help us refine corporate strategy to maximize our product pipeline. I
10/4/21 7:30:00 AM ET
$ACRX
$ADMP
Biotechnology: Pharmaceutical Preparations
Health Care
AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors
REDWOOD CITY, Calif., March 31, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Marina Bozilenko as an independent member of the company's Board of Directors. Ms. Bozilenko has over 30 years of investment banking and other healthcare industry experience, including raising more than $30 billion in capital and executing numerous M&A transactions. She currently serves as a strategic advisor to William Blair & Company, a firm she joined in 2010 as head of biotech & pharma and managing director.
3/31/21 8:30:00 AM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care

AcelRx Announces Rebranding With Name Change to Talphera, Inc.
Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10 SAN MATEO, Calif., Jan. 9, 2024 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the rebranding of the Company, with a name change to Talphera, Inc. ("Talphera"). The rebrand decision was made to reflect the Company's strategy of developing and commercializin
1/9/24 9:05:00 AM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonstrate challenges physicians have with heparin and citrate, the two currently available CRRT anticoagulants SAN MATEO, Calif., Dec. 12, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a quantitative market research study evaluating current U.S. physician anticoagulation use during continuous renal replacement therapy (CRRT) in patients with acute kidney injury in the intensive care unit. Th
12/12/23 8:30:00 AM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints planned to initiate in Q4 2023 with topline data expected mid-2024; clinical site readiness is currently underway Niyad would be the first and only approved regional anticoagulant in the U.S. for the extracorporeal circuit, if approved by the FDA SAN MATEO, Calif., Oct. 3, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, t
10/3/23 8:30:00 AM ET
$ACRX
Biotechnology: Pharmaceutical Preparations
Health Care

AcelRx Pharmaceuticals Q3 2023 Gaap EPS $(0.08) Beats $(0.28) Estimate, Sales $117.00K Miss $130.00K Estimate

Chat with this insight

Recent Analyst Ratings for $ACRX

$ACRX Financials

Live finance-specific insights

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

$ACRX Market Insights

Live Market Insights

AcelRx Pharmaceuticals Announces Rebranding With Name Change to Talphera; To Trade On Nasdaq Under Ticker Symbol "TLPH" Effective Jan. 10, 2024

AcelRx Pharmaceuticals Announces Publication Of Study Evaluating Anticoagulation Practices For Continuous Renal Replacement Therapy In The U.S.

Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket

$ACRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on AcelRx Pharmaceuticals with a new price target

$ACRX SEC Filings

SEC Form EFFECT filed by AcelRx Pharmaceuticals Inc.

SEC Form 424B7 filed by AcelRx Pharmaceuticals Inc.

SEC Form S-3 filed by AcelRx Pharmaceuticals Inc.

$ACRX Leadership Updates

Live Leadership Updates

AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors

Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors

AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors

$ACRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ACRX Press Releases

Fastest customizable press release news feed in the world

Dasu Badri N covered exercise/tax liability with 1,618 shares, decreasing direct ownership by 9% to 17,153 units (SEC Form 4)

Palmer Pamela P covered exercise/tax liability with 1,602 shares, decreasing direct ownership by 4% to 35,344 units (SEC Form 4)

Asadorian Raffi covered exercise/tax liability with 1,790 shares, decreasing direct ownership by 8% to 20,291 units (SEC Form 4)

AcelRx Announces Rebranding With Name Change to Talphera, Inc.

AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

$ACRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D filed by AcelRx Pharmaceuticals Inc.

$ACRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Angotti Vincent J. bought $7,268 worth of shares (10,000 units at $0.73), increasing direct ownership by 11% to 101,805 units (SEC Form 4)

Recent Analyst Ratings for
$ACRX

$ACRX
Financials

$ACRX
Market Insights

$ACRX
Analyst Ratings

$ACRX
SEC Filings

$ACRX
Leadership Updates

$ACRX
Insider Trading

$ACRX
Press Releases

$ACRX
Large Ownership Changes

$ACRX
Insider Purchases